Education
About Us
Working with TipRanks
Follow Us
Sanofi (FR:SAN)
:SAN
Top Page
Sanofi
(OTC:SAN)
Select Model
Select Model
Rating:77Outperform
Price Target:
€97.00
▲(11.75% Upside)
Sanofi's strong earnings call performance and attractive valuation are the most significant factors contributing to its overall score. The company's solid financial performance and strategic growth initiatives further support its position. However, technical indicators suggest caution due to potential overbought conditions.
Positive Factors
Negative Factors
Sanofi (SAN) vs. iShares MSCI France ETF (EWQ)
Market Cap
$105.83B
Dividend Yield4.52%
Average Volume (3M)2.27M
Price to Earnings (P/E)11.7
Beta (1Y)0.78
Revenue Growth-9.82%
EPS Growth119.10%
CountryFR
Employees82,878
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)1.59
Shares Outstanding1,227,469,000
10 Day Avg. Volume2,313,951
30 Day Avg. Volume2,268,255
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit3.51
Enterprise Value/Ebitda11.45
Forecast
1Y Price Target
$105.66Price Target Upside21.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Sanofi Business Overview & Revenue Model
Company DescriptionSanofi is a global healthcare company headquartered in Paris, France, specializing in pharmaceuticals and vaccines. The company operates in several key sectors, including prescription pharmaceuticals, vaccines, consumer healthcare products, and rare diseases. Sanofi's core products include a wide range of medications for diabetes, cardiovascular diseases, immunology, and oncology, as well as vaccines under its Sanofi Pasteur division.
How the Company Makes MoneySanofi generates revenue primarily through the sale of prescription pharmaceuticals, which includes both branded and generic medications. The company also earns significant income from its vaccine division, Sanofi Pasteur, which produces vaccines for infectious diseases. Key revenue streams include sales of diabetes treatments such as Lantus and Toujeo, cardiovascular drugs, and oncology products. Additionally, Sanofi's consumer healthcare segment contributes to its revenue through over-the-counter products. Strategic partnerships with other pharmaceutical firms and research institutions for collaborative drug development and licensing also enhance its earnings potential. Overall, Sanofi's diverse portfolio and global market presence are critical to its financial success.
Sanofi Earnings Call Summary
Earnings Call Date:Jul 31, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Oct 24, 2025
Earnings Call Sentiment Positive
Sanofi reported strong growth and successful new product launches, with significant gains in Dupixent and vaccines. Strategic acquisitions and sustainability leadership were also positive. However, challenges in the flu market and mixed results for itepekimab in COPD, along with potential future tariff impacts, present areas of concern.Q2-2025 Updates
Positive Updates
Strong Sales Growth
Sanofi delivered double-digit sales growth with net sales increasing by 10.1% at constant exchange rate in Q2 2025.
Successful New Launches
New launches generated close to EUR 1 billion in sales, contributing to 10% of total sales and 25% of growth in Q2.
Dupixent Performance
Dupixent sales reached EUR 3.8 billion, up 21% in Q2, with significant contributions from new indications like COPD.
Vaccine Business Growth
Vaccine sales increased by 10.3% in Q2, driven by Beyfortus expansion and flu season performance.
Strategic Acquisitions
Completed acquisitions of Blueprint Medicines and Vicebio, strengthening positions in rare diseases and vaccines.
Sustainability Leadership
Sanofi ranked as the world's 10th most sustainable company by TIME and #1 in pharma and biotech.
Improved Financial Performance
Gross margin improved by 1.5 percentage points, and business EPS was EUR 1.59, up 8.3%.
Negative Updates
Challenges in Flu Market
Flu sales expected to decrease by mid-teens percentage due to competitive pricing pressures in the U.S. and Germany.
Mixed Results for Itepekimab
Mixed Phase III results for itepekimab in COPD, with one study failing to meet endpoints.
Potential Impact of U.S. Tariffs
Potential U.S. tariffs on EU exports could impact future financial results, though 2025 impact expected to be limited.
Company Guidance
During the Q2 2025 conference call, Sanofi refined its 2025 sales guidance to a high single-digit percentage growth at constant exchange rates, highlighting strong quarterly performance with double-digit sales growth driven by new launches and key products such as Dupixent, which saw sales rise by 21% to €3.8 billion. The company reported a 10.1% increase in net sales at constant exchange rates, with gross margin improving by 1.5 points. The vaccine business also grew by 10.3%, supported by the expansion of Beyfortus and the late flu season in the Northern Hemisphere. The launch of new products contributed nearly €1 billion in sales during Q2, accounting for 10% of total sales. Sanofi also emphasized ongoing strategic investments in R&D, which saw a 17.7% increase, and the successful completion of the Blueprint Medicines acquisition, enhancing its position in rare diseases. Despite challenges, the company maintained its full-year EPS guidance of low double-digit growth at constant exchange rates.Sanofi Financial Statement Overview
Summary
Sanofi exhibits strong profitability with a consistent gross profit margin and solid balance sheet. However, a slight dip in revenue and cash flow poses challenges, though operational efficiency and prudent leverage remain strengths.Income Statement
Sanofi's income statement demonstrates stable profitability with a consistent gross profit margin around 70% and a net profit margin above 14% for TTM (Trailing-Twelve-Months). However, revenue has seen a slight decrease from 2023 to 2024, indicating a need for growth acceleration. The EBIT and EBITDA margins remain strong, suggesting efficient operational management.78
Positive
Balance Sheet
The balance sheet reflects a solid equity position with a debt-to-equity ratio of 0.28 for TTM, indicating conservative leverage. The company maintains a healthy equity ratio around 56%, showcasing strong asset backing. Despite a slight increase in total debt, the overall financial health appears robust.82
Very Positive
Cash Flow
Sanofi's cash flow statement shows a strong free cash flow to net income ratio, evidencing effective cash management. However, the free cash flow has decreased significantly from 2023 to TTM, highlighting potential challenges in sustaining cash flow. The operating cash flow remains positive, supporting operational needs efficiently.75
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 43.13B | 44.29B | 46.03B | 45.39B | 39.17B | 37.37B |
| Gross Profit | 30.89B | 31.08B | 31.80B | 31.70B | 26.92B | 25.21B |
| EBITDA | 9.47B | 11.03B | 12.00B | 14.06B | 11.29B | 17.51B |
| Net Income | 9.13B | 5.56B | 5.40B | 8.37B | 6.22B | 12.29B |
Balance Sheet | ||||||
| Total Assets | 124.96B | 132.80B | 126.46B | 126.72B | 120.24B | 114.41B |
| Cash, Cash Equivalents and Short-Term Investments | 15.36B | 7.93B | 8.71B | 12.74B | 10.10B | 13.91B |
| Total Debt | 22.29B | 17.91B | 18.42B | 21.21B | 22.41B | 23.68B |
| Total Liabilities | 54.68B | 54.94B | 52.11B | 51.57B | 51.21B | 51.16B |
| Stockholders Equity | 70.01B | 77.51B | 74.04B | 74.78B | 68.68B | 63.11B |
Cash Flow | ||||||
| Free Cash Flow | 12.04B | 5.89B | 8.64B | 8.32B | 8.48B | 5.33B |
| Operating Cash Flow | 13.31B | 9.08B | 10.26B | 10.53B | 10.52B | 7.45B |
| Investing Cash Flow | 6.96B | -4.41B | -6.20B | -2.08B | -7.30B | 3.59B |
| Financing Cash Flow | -10.93B | -5.76B | -8.05B | -5.82B | -7.06B | -6.49B |
Sanofi Technical Analysis
Positive
86.80
Price Trends
82.44
Positive
84.10
Positive
89.60
Negative
Market Momentum
0.52
Negative
62.74
Neutral
92.93
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:SAN, the sentiment is Positive. The current price of 86.8 is above the 20-day moving average (MA) of 80.77, above the 50-day MA of 82.44, and below the 200-day MA of 89.60, indicating a neutral trend. The MACD of 0.52 indicates Negative momentum. The RSI at 62.74 is Neutral, neither overbought nor oversold. The STOCH value of 92.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:SAN.
Sanofi Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $105.83B | 11.75 | 8.39% | 4.52% | -9.82% | 119.10% | |
73 Outperform | €13.78B | 36.40 | 9.69% | 0.77% | 8.28% | -8.08% | |
70 Outperform | €9.61B | 21.46 | 10.82% | 1.20% | 9.57% | -34.30% | |
67 Neutral | €11.46B | 26.85 | 11.27% | 0.97% | 6.25% | 18.93% | |
64 Neutral | €19.33B | 85.81 | 5.71% | 0.35% | 5.44% | 30.04% | |
63 Neutral | €2.71B | 20.34 | 12.92% | 0.45% | 6.97% | -5.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
FR:SAN
Sanofi
85.78
-10.83
-11.21%
FR:BIM
bioMerieux
116.60
11.18
10.61%
FR:ERF
Eurofins Scientific
62.14
7.63
14.01%
FR:IPN
Ipsen
116.70
4.81
4.30%
FR:DIM
Sartorius Stedim Biotech
198.60
17.44
9.63%
FR:VIRP
Virbac SA
323.00
-49.82
-13.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.